NCT03659747已完成不适用
Effect of Probiotic Supplementation on Lactose Maldigestion Induced by Fat-free Milk: Randomized, Double-blind, Placebo-controlled, Crossover, Acute Lactose Challenge
Danisco2 个研究点 分布在 1 个国家目标入组 34 人开始时间: 2018年9月11日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 34
- 试验地点
- 2
- 主要终点
- Non-inferiority in breath hydrogen concentration (BHC, ppm) of probiotic group compared to lactase group (positive control), measured by the iAUC analysis
研究概览
简要总结
The main objective of the study is to investigate the effect of probiotic supplementation on lactose maldigestion.
详细描述
Primary endpoint is defined as the difference in breath hydrogen concentration (BHC, ppm) in lactase and probiotic groups compared to placebo and non-inferiority in breath hydrogen concentration (BHC, ppm) in probiotic group compared to lactase group, measured by the incremental area under curve (iAUC) analysis.
To characterize the benefit of the investigational product (IP) the following secondary endpoints will be analyzed:
Breath test:
- Breath hydrogen peak value (ppm) in lactase and probiotic groups compared to placebo
- Cumulative breath hydrogen (ppm) in lactase and probiotic groups compared to placebo
Acute gastrointestinal symptoms (severity or presence/absence to be defined on a Likert scale) in lactase and probiotic groups compared to placebo:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 25 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary, written, informed consent to participate in the study
- •Agreement to comply with the protocol and study restrictions
- •Healthy females and males of age 25 to 60 years (inclusive)
- •Self-declared or medically diagnosed lactose intolerance
- •Increase of more than 20 ppm in breath hydrogen within 3 h from the baseline fasting breath hydrogen value at V2
- •Participants who agree to maintain their usual dietary habits throughout the trial period
- •Participants who agree not to consume probiotics, prebiotics, fermented milk, and/or yogurt containing probiotics during and two weeks before Visit 3 (2 weeks after pre-screening visit)
- •Females of child-bearing potential who agree to use a medically approved methods of birth control
- •Ability of the participant (in the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects
- •Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research
排除标准
- •Gastrointestinal disorder or disease (e.g. Crohn's disease, ulcer, irritable bowel syndrome (IBS), Celiac disease, small intestinal bacterial overgrowth (SIBO), pancreatitis and disorders affecting gastrointestinal motility)
- •Diagnosed type 1 or type 2 diabetes
- •Prior abdominal surgery that, in the opinion of the investigator, may present a risk for the participant or affect study results
- •Ongoing or recent (last 1 months) antibiotic treatment.
- •Use of laxatives or drugs known to affect gut motility 1 month preceding the screening visit and during the study
- •Ongoing or recurrent use of proton pump inhibitors
- •Colonoscopy within 3 months before screening
- •History of recurrent colon cleansing and/or a colon cleansing within 3 months before screening
- •Gastrointestinal infection within 1 month before screening or during the trial
- •Clinically significant underlying systemic illness that may preclude the participant's ability to complete the trial or that may affect the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness)
- •History of diagnosed coronary heart disease/cardiovascular disease or artificial heart valve.
- •Any obstructive or restrictive respiratory syndrome/disease that may impact breath test (e.g. asthma or chronic obstructive pulmonary disease (COPD))
- •Use of tobacco, snuff, nicotine and e-cigarette
- •History of or current abuse of drugs, alcohol or medication (self- reported)
- •Self-declared use of illicit drugs
- •Pregnant or lactating female, or pregnancy planned during study period
- •Participants under administrative or legal supervision.
- •Participation in another study with any investigational product within 60 days of screening
- •Abnormal values in safety blood tests at V1 i.e. clinically significant or >2x upper limit of normal, unless the deviation is justified by a previously known not clinically relevant condition (e.g. Gilbert's syndrome)
- •Other reasons that, in the opinion of the Investigator, make the participant unsuitable for enrolment
研究组 & 干预措施
Probiotic
Experimental
- 6 g sachet containing probiotic powder (1.8 x 10^12 colony forming units (CFU) Probiotic) in sachet
- One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
干预措施: Probiotic (Dietary Supplement)
Lactrase
Active Comparator
- 6 g sachet containing 4500 FCC units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier
- One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
干预措施: Lactrase (Dietary Supplement)
Placebo
Placebo Comparator
- 6 g sachet containing placebo powder (maltodextrin) in sachet
- One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
干预措施: Placebo (Other)
结局指标
主要结局
Non-inferiority in breath hydrogen concentration (BHC, ppm) of probiotic group compared to lactase group (positive control), measured by the iAUC analysis
时间窗: approximately 40 days
Difference in breath hydrogen concentration (BHC, ppm) in probiotic group compared to placebo, measured by the iAUC analysis
时间窗: approximately 40 days
Difference in breath hydrogen concentration (BHC, ppm) in lactase group compared to placebo, measured by the iAUC analysis
时间窗: approximately 40 days
次要结局
- Difference in the severity of flatulence in lactase group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in the severity of nausea in lactase group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in breath hydrogen concentration (BHC, ppm) in lactase group compared to placebo, measured by cumulative breath hydrogen value(approximately 40 days)
- Difference in the severity of abdominal pain in lactase group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in breath hydrogen concentration (BHC, ppm) in probiotic group compared to placebo, measured by breath hydrogen peak value(approximately 40 days)
- Difference in the presence of diarrhea in lactase group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in the presence of diarrhea in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in the severity of abdominal pain in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in the severity of nausea in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in the presence of vomiting in lactase group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in the severity of flatulence in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in the severity of bloating in lactase group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in breath hydrogen concentration (BHC, ppm) in lactase group compared to placebo, measured by breath hydrogen peak value(approximately 40 days)
- Difference in breath hydrogen concentration (BHC, ppm) in probiotic group compared to placebo, measured by cumulative breath hydrogen value(approximately 40 days)
- Difference in the presence of vomiting in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in the severity of bloating in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in the presence of bowel movements in probiotic group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
- Difference in the presence of bowel movements in lactase group compared to placebo, as defined by the gastrointestinal symptom survey(approximately 40 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Study to Investigate the Treatment Benefit of Probiotic Lactobacillus Crispatus M247 in Women Undergoing Homologous Level 2 Assisted Reproductive Technology (ART) ProceduresFertility IssuesNCT05871242Dr. Amjad Khan160
Unknown
2 期
The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV PatientsDiarrheaHIV InfectionsBacterial VaginosisNCT00536848National Institute for Medical Research, Tanzania65
已完成
不适用
The Effect of a Probiotic Intervention in Healthy Subjects and Patients With Atopic DermatitisAtopic DermatitisNCT00550472University of Jena30
已完成
不适用
The Effect of Supplementation With Species of Lactobacillus on Anthropometric MeasurementsOverweight and ObesityNCT02448940Urmia University of Medical Sciences72
已完成
不适用
Effect of Probiotic Supplementation on Lactose Maldigestion Induced by Lactose SolutionLactose IntoleranceNCT03814668Danisco34